A paratope is the antigen-binding site of an antibody, formed by specific amino acid residues in the variable regions of the heavy and light chains. It recognizes and binds to a complementary epitope on an antigen through non‑covalent interactions.
Structure and Function
Each antibody contains two identical paratopes situated at the ends of its Fab fragments. These regions are composed of loops in the variable domains of the heavy and light chains known as complementarity‑determining regions (CDRs). Three CDRs from each chain—CDR1, CDR2 and CDR3—combine to form a unique surface that can bind a specific antigen. The shape and chemical properties of a paratope are generated by the sequence of amino acids in these loops and by the framework regions that support them. Paratopes interact with epitopes via hydrogen bonds, van der Waals forces, hydrophobic contacts and electrostatic attractions. Because these interactions are non‑covalent, binding is reversible and can be modulated by affinity and avidity. During an immune response, B cells undergo somatic hypermutation and selection in germinal centers, altering the sequence of their CDRs. This process, known as affinity maturation, refines the paratope to improve binding strength to the target antigen. The specificity of a paratope determines which antigens an antibody can recognize, making it central to immune defense and to the design of therapeutic antibodies. In some cases, paratopes may cross‑react with structurally similar epitopes, leading to broad protective responses or unwanted autoimmunity.
Structural Insights
X‑ray crystallography and cryo‑electron microscopy have revealed how paratopes engage diverse antigens. For example, antibodies targeting influenza haemagglutinin use a long CDR3 loop to penetrate the receptor‑binding pocket, while those neutralizing HIV gp120 often have extended loops that reach conserved regions shielded by glycans. Therapeutic antibodies such as trastuzumab and cetuximab have paratopes tailored to bind specific domains on the HER2 and EGFR receptors. Engineered nanobodies derived from camelid heavy‑chain antibodies possess single paratopes capable of accessing recessed epitopes inaccessible to conventional antibodies. In vaccine design, the goal is to elicit antibodies whose paratopes mimic these high‑affinity interactions. Paratopes illustrate how subtle variations in amino acid sequence create precise antigen‑binding surfaces. Understanding their structure–function relationships guides vaccine development and the engineering of antibodies for therapy and diagnostics. Related Terms: Epitope, Antibody, Complementarity-Determining Region, Affinity Maturation, Antigen-Antibody Complex